Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
6.360
-0.060 (-0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld
June 27, 2023
MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end.
Via
Benzinga
FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
June 22, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 22, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Announces Election of All Six Company Nominees at Annual Meeting
June 21, 2023
From
Mind Medicine
Via
Business Wire
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
June 20, 2023
From
Mind Medicine
Via
Business Wire
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
June 17, 2023
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.
Via
Talk Markets
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
June 15, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed Adjourns Annual General Meeting of Shareholders
June 15, 2023
From
Mind Medicine
Via
Business Wire
Major Psychedelic Compound-Based Research & Development Stocks: June Update
June 10, 2023
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index
Via
Talk Markets
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
June 09, 2023
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
Via
Benzinga
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
June 09, 2023
From
MindMed
Via
Business Wire
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
June 08, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
June 07, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed to Host Investor Day June 2023
June 07, 2023
From
Mind Medicine
Via
Business Wire
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
June 05, 2023
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
Via
Benzinga
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
June 05, 2023
From
MindMed
Via
Business Wire
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
June 02, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
MindMed to Participate at Upcoming Investor Conferences
June 01, 2023
From
Mind Medicine
Via
Business Wire
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
May 30, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
May 30, 2023
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis...
Via
Benzinga
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
May 25, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
May 25, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
May 25, 2023
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t
Via
Benzinga
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
May 25, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
May 24, 2023
From
MindMed
Via
Business Wire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
May 19, 2023
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.
Via
Benzinga
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
May 17, 2023
From
MindMed
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.